Air Industries Group — Q1 2024 Form 10-Q
Business context and period: The company manufactures precision components and assemblies for aerospace and defense customers. This unaudited report covers the three months ended March 31, 2024, compared with Q1 2023. Its products serve military and commercial platforms; sales are concentrated among major aerospace and defense contractors.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Net sales | $14.061 million | $12.549 million; up 12.0% |
| Gross profit / margin | $1.906 million / 13.6% | $1.880 million / 15.0% |
| Operating expenses | $2.165 million | $2.038 million |
| Operating loss | $259,000 | $158,000 |
| Net loss / diluted loss per share | $706,000 / $0.21 | $618,000 / $0.19 |
| Cash from operations | Used $232,000 | Generated $1.438 million |
| Cash at period end | $225,000 | $1.125 million at March 31, 2023 |
| Working capital | $11.610 million | $12.117 million at December 31, 2023 |
Gross margin declined as product mix, platform mix, and operating efficiencies changed. Operating expenses rose in dollars, principally on professional fees and IT and cybersecurity improvement costs, but fell as a share of sales to 15.4% from 16.2%. Interest expense was $462,000, down 2.9%; the facility’s average interest rate rose to 7.85% from 7.04%.
At March 31, total assets were $50.262 million, total liabilities $35.716 million, and stockholders’ equity $14.546 million. Total debt was $23.936 million, including $16.119 million under the Webster credit facility and $6.162 million of related-party notes. Current debt was $16.309 million. Inventory was $29.359 million; customer deposits were $3.158 million. The filing reports approximately $9.078 million of revolver borrowing capacity, subject to collateral availability and lender discretion.
Q1 investing cash outflow was $111,000, mainly for property and equipment; financing activities provided $222,000. Cash fell $121,000 during the quarter. The company expects to invest approximately $2 million in equipment during the remainder of 2024.
Material changes and outlook
- Sales increased 12.0%, led in part by commercial revenue, which rose to $3.676 million from $2.517 million; military revenue was $10.385 million versus $10.032 million.
- Gross profit increased only $26,000 as cost of sales grew faster than revenue, reducing gross margin by 1.4 percentage points. Net loss widened by $88,000.
- Operating cash flow shifted from $1.438 million provided in Q1 2023 to $232,000 used in Q1 2024, partly reflecting use of customer advances received in 2023 for long-lead raw materials.
- Backlog rose to $99.3 million from $98.1 million at December 31, 2023. Management expects sales to increase in 2024 versus 2023 and further in 2025 and beyond, citing backlog and anticipated funded orders. It expects a substantial portion of backlog to convert to sales within 24 months, subject to timely supplies, processing, and customer acceptance. Management also expresses confidence in improving sales and attaining profitability; these are expectations, not guaranteed results.
- Management reported total unfilled contract values of $179.1 million, including backlog and potential orders under previously awarded long-term agreements.
Risks, contingencies, and unusual items
- Going concern and covenant default: The company failed to meet the credit facility’s required fixed charge coverage ratio as of March 31, 2024: 0.86 versus 1.10 required for the six-month period. It had not obtained a waiver as of filing and stated a waiver might not be granted. The lender could accelerate debt, raise interest, restrict revolver advances, or retain funds remitted to the required collection account. Management concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern for the year following issuance of the statements.
- The term loan balance of $4.814 million was classified as current because of the covenant breach and possible callable status. Management is discussing a waiver and adjusted or new financing with its lender. It estimates approximately $944,000 of required credit-facility principal payments over the next 12 months, excluding possible acceleration.
- Customer concentration is significant: RTX and Lockheed Martin represented 30.7% and 25.9% of Q1 sales, respectively; RTX represented 52.6% of receivables at quarter-end. The company also relies on sole-source suppliers for some production inputs.
- A lawsuit by Contract Pharmacal seeks $700,000 in damages. The company disputes the claim and intends to contest it; it says it anticipates nothing of consequence over the next 12 months. The filing does not quantify a probable loss.
- Management found internal control over financial reporting ineffective at March 31, 2024. A previously reported material weakness related to IT systems remained unremediated while new controls continued to be tested.
- Inventory reserves were $3.502 million, up from $3.243 million at year-end. The company also notes that sales and margins are sensitive to customer timing, product mix, production capacity, and supply availability.
Important facts for investors to verify
- Whether the lender grants a covenant waiver, continues to provide revolver funding, and agrees to revised or replacement financing.
- Available liquidity in practice, given only $225,000 of reported cash, lender-controlled cash receipts, and borrowing capacity subject to collateral and lender discretion.
- Whether backlog and anticipated LTA orders convert to funded, deliverable sales on schedule and at adequate margins.
- Progress in restoring gross margins, generating positive operating cash flow, and meeting upcoming debt covenants and payments.
- Remediation and testing of the IT-related material weakness, as well as developments in the Contract Pharmacal litigation and inventory reserves.